Date: 2018-05-03
Type of
information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Celyad (Belgium)
Product: CYAD-01 - NKR-2 (NKG2D CAR T-Cell)
Action
mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. NKG2D CAR T-Cell is an autologous chimeric antigen receptor T lymphocyte (CAR T-cell) therapy constructed using the native sequence of non-engineered natural killer cell (NK cell) receptors which, unlike traditional CAR technologies such as those targeting the CD19 antigen, have the potential to target a broad range of solid tumors and blood cancers by targeting ligands present on numerous cancer types. NKG2D CAR T-Cell could be also a potential new treatment option for patients with solid tumors such as breast, colorectal, lung, liver, ovarian and bladder cancer. The research underlying this technology was originally conducted at Dartmouth College by Professor Charles Sentman, and has been published in numerous peer-reviewed publications such as Journal of Immunology, Cancer Research and Blood.
Disease: metastatic colorectal cancer
Therapeutic
area: Cancer - Oncology
Country: Belgium
Trial
details:
- LINK is an open-label Phase I trial evaluating the safety and clinical activity of multiple doses of CYAD-01, adopting a loco-regional approach in treating patients with CYAD-01 administration through multiple hepatic transarterial injections to colorectal cancer patients diagnosed with unresectable liver metastases. The dose escalation design of LINK includes three dose levels: 3x108, 1x109 and 3x109 of CYAD-01. At each dose, the patients will receive three successive administrations, two weeks apart at the specified dose. No adverse events have been reported in the first patient enrolled, who has received his three consecutive CYAD-01 administrations at the first dose level.
- (NCT03370198)
Latest
news:
- • On May 3, 2018, Celyad announced the successful injection of the first patients in the LINK trial targeting metastatic colorectal patients. No toxicity has been observed to date in first patient enrolled in the LINK trial (hepatic transarterial administrations)
- • On March 29, 2018, Celyad announced that the company will present updates on the LINK Phase I clinical trial at the American Association for Cancer Research (AACR) Annual Meeting .
- Poster Title: The LINK clinical trial: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer.
Is
general: Yes
